These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

914 related items for PubMed ID: 19148529

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2. Positive correlation of tissue inhibitor of metalloproteinase-3 and death-associated protein kinase hypermethylation in head and neck squamous cell carcinoma.
    Nayak CS, Carvalho AL, Jeronimo C, Henrique R, Kim MM, Hoque MO, Chang S, Jiang WW, Koch W, Westra W, Sidransky D, Califano J.
    Laryngoscope; 2007 Aug; 117(8):1376-80. PubMed ID: 17592394
    [Abstract] [Full Text] [Related]

  • 3. Promoter hypermethylation of multiple genes in early gastric adenocarcinoma and precancerous lesions.
    Zou XP, Zhang B, Zhang XQ, Chen M, Cao J, Liu WJ.
    Hum Pathol; 2009 Nov; 40(11):1534-42. PubMed ID: 19695681
    [Abstract] [Full Text] [Related]

  • 4. Patterns of gene promoter methylation in squamous cell cancer of the head and neck.
    Hasegawa M, Nelson HH, Peters E, Ringstrom E, Posner M, Kelsey KT.
    Oncogene; 2002 Jun 20; 21(27):4231-6. PubMed ID: 12082610
    [Abstract] [Full Text] [Related]

  • 5. Detecting methylation patterns of p16, MGMT, DAPK and E-cadherin genes in multiple myeloma patients.
    Yuregir OO, Yurtcu E, Kizilkilic E, Kocer NE, Ozdogu H, Sahin FI.
    Int J Lab Hematol; 2010 Apr 20; 32(2):142-9. PubMed ID: 19302404
    [Abstract] [Full Text] [Related]

  • 6. O6-methylguanine-DNA methyltransferase gene: epigenetic silencing and prognostic value in head and neck squamous cell carcinoma.
    Zuo C, Ai L, Ratliff P, Suen JY, Hanna E, Brent TP, Fan CY.
    Cancer Epidemiol Biomarkers Prev; 2004 Jun 20; 13(6):967-75. PubMed ID: 15184253
    [Abstract] [Full Text] [Related]

  • 7. Correlation between promoter hypermethylation of GSTP1 and response to chemotherapy in diffuse large B cell lymphoma.
    Nakamichi I, Tomita Y, Zhang B, Sugiyama H, Kanakura Y, Fukuhara S, Hino M, Kanamaru A, Ogawa H, Aozasa K.
    Ann Hematol; 2007 Aug 20; 86(8):557-64. PubMed ID: 17508213
    [Abstract] [Full Text] [Related]

  • 8. Quantitative promoter hypermethylation analysis of cancer-related genes in salivary gland carcinomas: comparison with methylation-specific PCR technique and clinical significance.
    Lee ES, Issa JP, Roberts DB, Williams MD, Weber RS, Kies MS, El-Naggar AK.
    Clin Cancer Res; 2008 May 01; 14(9):2664-72. PubMed ID: 18451230
    [Abstract] [Full Text] [Related]

  • 9. The p16 (CDKN2a/INK4a) tumor-suppressor gene in head and neck squamous cell carcinoma: a promoter methylation and protein expression study in 100 cases.
    Ai L, Stephenson KK, Ling W, Zuo C, Mukunyadzi P, Suen JY, Hanna E, Fan CY.
    Mod Pathol; 2003 Sep 01; 16(9):944-50. PubMed ID: 13679459
    [Abstract] [Full Text] [Related]

  • 10. The methylation status and protein expression of CDH1, p16(INK4A), and fragile histidine triad in nonsmall cell lung carcinoma: epigenetic silencing, clinical features, and prognostic significance.
    Nakata S, Sugio K, Uramoto H, Oyama T, Hanagiri T, Morita M, Yasumoto K.
    Cancer; 2006 May 15; 106(10):2190-9. PubMed ID: 16598757
    [Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12. Promoter hypermethylation and expression profile of MGMT and CDH1 genes in oral cavity cancer.
    Kordi-Tamandani DM, Moazeni-Roodi AK, Rigi-Ladiz MA, Hashemi M, Birjandian E, Torkamanzehi A.
    Arch Oral Biol; 2010 Oct 15; 55(10):809-14. PubMed ID: 20674887
    [Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14. Promoter methylation of RASSF1A, RARbeta and DAPK predict poor prognosis of patients with malignant mesothelioma.
    Fischer JR, Ohnmacht U, Rieger N, Zemaitis M, Stoffregen C, Kostrzewa M, Buchholz E, Manegold C, Lahm H.
    Lung Cancer; 2006 Oct 15; 54(1):109-16. PubMed ID: 16893590
    [Abstract] [Full Text] [Related]

  • 15. Promoter hypermethylation patterns of p16, O6-methylguanine-DNA-methyltransferase, and death-associated protein kinase in tumors and saliva of head and neck cancer patients.
    Rosas SL, Koch W, da Costa Carvalho MG, Wu L, Califano J, Westra W, Jen J, Sidransky D.
    Cancer Res; 2001 Feb 01; 61(3):939-42. PubMed ID: 11221887
    [Abstract] [Full Text] [Related]

  • 16. Comparison of promoter hypermethylation pattern in salivary rinses collected with and without an exfoliating brush from patients with HNSCC.
    Sun W, Zaboli D, Liu Y, Arnaoutakis D, Khan T, Wang H, Koch W, Khan Z, Califano JA.
    PLoS One; 2012 Feb 01; 7(3):e33642. PubMed ID: 22438973
    [Abstract] [Full Text] [Related]

  • 17. Aberrant promoter hypermethylation in serum DNA from patients with silicosis.
    Umemura S, Fujimoto N, Hiraki A, Gemba K, Takigawa N, Fujiwara K, Fujii M, Umemura H, Satoh M, Tabata M, Ueoka H, Kiura K, Kishimoto T, Tanimoto M.
    Carcinogenesis; 2008 Sep 01; 29(9):1845-9. PubMed ID: 18632757
    [Abstract] [Full Text] [Related]

  • 18. Value of p16INK4a and RASSF1A promoter hypermethylation in prognosis of patients with resectable non-small cell lung cancer.
    Wang J, Lee JJ, Wang L, Liu DD, Lu C, Fan YH, Hong WK, Mao L.
    Clin Cancer Res; 2004 Sep 15; 10(18 Pt 1):6119-25. PubMed ID: 15447998
    [Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 46.